Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBC 107

Drug Profile

SBC 107

Alternative Names: SBC-107; YDC-104

Latest Information Update: 30 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALBORADA Drug Discovery Institute
  • Developer ALBORADA Drug Discovery Institute; SapiensBio; YD Global Life Science
  • Class Antidementias
  • Mechanism of Action Eukaryotic initiation factor-2b modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 11 Nov 2022 ALBORADA Drug Discovery Institute, SapiensBio and YD Global Life Sciences enters into collaboration agreement to develop Eukaryotic initiation factor 2B (eIF2B) modulators for neurodegenerative disorders
  • 05 Jun 2022 Early research in Alzheimer's disease in South Korea (unspecified route) as of June 2022 (YD Global Life Science pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top